DACHA STRATEGIC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more
DACHA STRATEGIC (7DC) - Net Assets
Latest net assets as of June 2025: €37.24 Million EUR
Based on the latest financial reports, DACHA STRATEGIC (7DC) has net assets worth €37.24 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€44.42 Million) and total liabilities (€7.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €37.24 Million |
| % of Total Assets | 83.83% |
| Annual Growth Rate | 14.63% |
| 5-Year Change | -0.95% |
| 10-Year Change | N/A |
| Growth Volatility | 40.13 |
DACHA STRATEGIC - Net Assets Trend (2019–2024)
This chart illustrates how DACHA STRATEGIC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DACHA STRATEGIC (2019–2024)
The table below shows the annual net assets of DACHA STRATEGIC from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €39.86 Million | -2.28% |
| 2023-12-31 | €40.79 Million | -4.06% |
| 2022-12-31 | €42.51 Million | +4.59% |
| 2021-12-31 | €40.65 Million | +1.02% |
| 2020-12-31 | €40.24 Million | +99.87% |
| 2019-12-31 | €20.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DACHA STRATEGIC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1440.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €40.62 Million | 101.93% |
| Total Equity | €39.86 Million | 100.00% |
DACHA STRATEGIC Competitors by Market Cap
The table below lists competitors of DACHA STRATEGIC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sandhar Technologies Limited
NSE:SANDHAR
|
$81.99 Million |
|
Saigon Telecommunication & Technologies Corp
VN:SGT
|
$82.01 Million |
|
iClick Interactive Asia Group
NASDAQ:ICLK
|
$82.01 Million |
|
Pharmaniaga Bhd
KLSE:7081
|
$82.05 Million |
|
Community Bancorp. Common Stock
OTCQX:CMTV
|
$81.94 Million |
|
Inmocemento, S.A.
MC:IMC
|
$81.94 Million |
|
Sunrise Realty Trust, Inc.
NASDAQ:SUNS
|
$81.93 Million |
|
Solusi Tunas Pratama Tbk
JK:SUPR
|
$81.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DACHA STRATEGIC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,786,000 to 39,857,000, a change of -929,000 (-2.3%).
- Net loss of 1,703,000 reduced equity.
- New share issuances of 136,000 increased equity.
- Other factors increased equity by 638,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.70 Million | -4.27% |
| Share Issuances | €136.00K | +0.34% |
| Other Changes | €638.00K | +1.6% |
| Total Change | €- | -2.28% |
Book Value vs Market Value Analysis
This analysis compares DACHA STRATEGIC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.60x to 3.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.29 | €1.62 | x |
| 2020-12-31 | €0.48 | €1.62 | x |
| 2021-12-31 | €0.48 | €1.62 | x |
| 2022-12-31 | €0.50 | €1.62 | x |
| 2023-12-31 | €0.48 | €1.62 | x |
| 2024-12-31 | €0.47 | €1.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DACHA STRATEGIC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.30%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.22x
- Recent ROE (-4.27%) is below the historical average (-0.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 1.98% | 2.96% | 0.60x | 1.11x | €-1.62 Million |
| 2020 | 0.65% | 2.07% | 0.29x | 1.08x | €-3.76 Million |
| 2021 | 1.38% | 4.02% | 0.31x | 1.11x | €-3.50 Million |
| 2022 | 1.70% | 3.71% | 0.40x | 1.14x | €-3.53 Million |
| 2023 | -4.28% | -7.37% | 0.51x | 1.14x | €-5.82 Million |
| 2024 | -4.27% | -5.30% | 0.66x | 1.22x | €-5.69 Million |
Industry Comparison
This section compares DACHA STRATEGIC's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $2,003,667,851
- Average return on equity (ROE) among peers: -13.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DACHA STRATEGIC (7DC) | €37.24 Million | 1.98% | 0.19x | $81.97 Million |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $631.00 Million |
| ABL Diagnostics Société anonyme (9BK0) | $6.77 Million | 0.80% | 1.20x | $371.65K |
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | $1.04 Billion | -33.28% | 0.39x | $47.71 Million |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| DocCheck AG (AJ91) | $18.14 Million | 3.32% | 0.15x | $18.00 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Tempus AI (F3M) | $-1.38 Billion | 0.00% | 0.00x | $4.75 Billion |
| Pangenomic Health Inc. (LL3) | $2.24 Million | -118.14% | 0.15x | $4.82 Million |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.89 Million |